Liminatus Pharma LIMN
NASDAQ LIMN
$3.22 +0.11 (+3.54%)
As of: Oct 20, 2026 · 2:26 PM EDT

Liminatus Pharma (LIMN) Research & Development (2024 - 2026)

Updated

Liminatus Pharma (LIMN) recorded Research & Development of $600,000 in Q2 2026, up 50.0% from the prior quarter.

Analysis

Liminatus Pharma (LIMN) Research & Development (2024 - 2026) Analysis & Trends

On a TTM basis, Liminatus Pharma's Research & Development came in at $1 million as of Jun 30, 2026, up 180.1% year-over-year; for FY2024, it came in at $2.69 million.

  • The Q2 2026 figure is the highest quarterly Research & Development since Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 3.82 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 3.65 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 2.34 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 9.74 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 2.85 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 4.05 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 1.87 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 1.76 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 2.81 Bn
10 Liminatus Pharma 3.12 Mn -2.87 Mn - 600,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 600,000.00
Mar 31, 2026 400,000.00
Sep 30, 2024 357,066.00
Jun 30, 2024 714,134.00
API Access

Liminatus Pharma Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=LIMN&period=max&api_key=YOUR_API_KEY